Record Details

<p><strong>Low dose of <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab and <sup>131</sup>I-Rituximab induces G1arrest and apoptosis in Raji cells (Burkitt’s lymphoma)</strong></p>

Online Publishing @ NISCAIR

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement <p><strong>Low dose of <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab and <sup>131</sup>I-Rituximab induces G1arrest and apoptosis in Raji cells (Burkitt’s lymphoma)</strong></p>
 
Added Entry - Uncontrolled Name Suman, Shishu Kant
Kameswaran, Mythili
Dash, Ashutosh
 
Uncontrolled Index Term Anticancer; Cell death; Cytotoxicity; Fragmented antibody; Radioiodination
 
Summary, etc. <p class="Abstract" style="text-align: justify;">Radiolabeled fragmented F(ab')<sub>2</sub> antibodies had shown better therapeutic efficacy than radiolabeled intact antibodies in treating cancers.  In this study, we investigated the differences and similarities on the mechanism and extent of cell death in Raji cells (Burkitt’s lymphoma) in response to 370 kBq<sup> </sup>of <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab and <sup>131</sup>I-Rituximab up to 72 h. F(ab')<sub>2</sub> of Rituximab was prepared and characterized by SE-HPLC and SDS-PAGE. Fragmented and intact Rituximab were radioiodinated by Chloramine-T method. Toxicity and mechanism of cell death in Raji cells in response to <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab and <sup>131</sup>I-Rituximab were studied by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), LDH (lactate dehydrogenase), trypan blue exclusion, viability, apoptotic, caspase assays and cell cycle analysis. The cytotoxicity assays showed slow death of Raji cells up to 24 h in response to both <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab and <sup>131</sup>I-Rituximab. Cell cycle analysis at 30 h showed G1 arrest in Raji cells which led to its slow cell death up to 24 h.<strong> </strong>Elucidative assays to identify the molecular mechanism of death of G1arrested Raji cells showed apoptotic cell death at 40 h after treatment, which was validated by demonstrating caspase activation in arrested Raji cells. Toxicity studies and mechanism of cell death in Raji cells demonstrated comparable results when treated with equivalent doses (370 kBq) of radiolabeled antibodies indicating <sup>131</sup>I-F(ab')<sub>2</sub>-Rituximab as a potential radioimmunotherapeutic agent for patients with Non-Hodgkin’s lymphoma. <strong><em></em></strong></p>
 
Publication, Distribution, Etc. Indian Journal of Experimental Biology (IJEB)
2020-09-30 00:00:00
 
Electronic Location and Access application/pdf
http://op.niscair.res.in/index.php/IJEB/article/view/41204
 
Data Source Entry Indian Journal of Experimental Biology (IJEB); ##issue.vol## 58, ##issue.no## 10 (2020): IJEB [October 2020]
 
Language Note en